Multi-Specific Antibodies Binding A33 Antigen and DOTA Metal Complex for Colorectal Cancer
Summary
The USPTO published patent application US20260109765A1 filed by six named inventors covering multi-specific binding agents that bind A33 glycoprotein antigen and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), along with methods for detecting, preventing, and treating diseases expressing the A33 antigen, particularly colorectal cancer. The application was filed on 2025-05-07 and assigned Application No. 19201681. This represents a new intellectual property filing in the targeted cancer therapy space.
“Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 223 changes logged to date.
What changed
The USPTO published patent application US20260109765A1 covering multi-specific binding agents that simultaneously bind the A33 glycoprotein antigen and DOTA metal complex, with methods for detection, prevention, and therapeutic treatment of A33-expressing diseases, particularly colorectal cancer. The application names six inventors and includes CPC classifications spanning antibody constructs (C07K 16/2803), radiopharmaceuticals (A61K 51/0482), and oncology therapeutics (A61P 35/00).
For pharmaceutical and biotechnology entities engaged in targeted cancer therapy research, this published application establishes prior art in the multi-specific antibody space targeting A33-expressing cancers. Companies developing similar bispecific or multi-specific antibody constructs for colorectal cancer should review this publication for freedom-to-operate considerations and potential licensing opportunities.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF
Application US20260109765A1 Kind: A1 Apr 23, 2026
Inventors
Sarah CHEAL, Hong XU, Steven LARSON, Nai-Kong CHEUNG, Karl Dane WITTRUP, Alice TZENG
Abstract
Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.
CPC Classifications
C07K 16/2803 A61K 51/0482 A61P 35/00 A61K 2039/505 C07K 2317/24 C07K 2317/31 C07K 2317/622
Filing Date
2025-05-07
Application No.
19201681
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.